DW
Background
CFO and operator with fifteen years inside UK oncology and rare-disease biotechs, currently Managing Director at Kestrel Biopharma after CFO seats at Glasslake Therapeutics, Cantor Pharma and Halcyon Therapeutics. I've led Series A and B rounds with UK and European VCs, built finance functions from a single spreadsheet…
Experience10 yrsCompanies8
Career History
Jul 2023 – Present3 yrChief Financial Officer at Cantor PharmaLondon, England, United Kingdom
Series A11–50 FTEs£22M Series A extension
Brought in to clean up the cap table and run a £22M Series A extension; owns R&D tax credit reclaim and EIS compliance across the group.
Mar 2021 – Present5 yr 4 moChief Financial Officer at Glasslake TherapeuticsLondon, England, United Kingdom
Seed → Series A4 → 19 FTEs£14M Series AOncology · Small molecule
Built the finance function from scratch and led the £14M Series A with Cambridge Innovation Capital and Sofinnova as co-leads.
Mar 2021 – Present5 yr 4 moConsultant Finance Director at Ridgeline BioLondon, England, United Kingdom
Mar 2021 – Present5 yr 4 moChief Financial Officer at Halcyon TherapeuticsLondon, England, United Kingdom
Series B → Exit11–50 FTEsTarget-side trade sale
Ran the sell-side process end-to-end and closed a $180M trade sale to a US mid-cap; handled vendor DD, escrow structuring and EIS investor waterfall.
Education
Bachelor's degree — Westcliff Institute (1984–1988)